l-Arginine treatment improves angiogenic response and reduces matrix metalloproteinase activity in chronic heart failure patients with coronary artery disease

This study was undertaken to evaluate effects of l-arginine on the levels of key angiogenic regulators and matrix metalloproteinase (MMP) activity in sera of chronic heart failure (CHF) patients with CAD. Thirty-three patients were divided into two groups: 1) received only the standard treatment (control group, n = 13); 2) received l-arginine intravenous infusions in the dose of 4.2 g /100 mL for 7 days, followed by oral supplementation in the daily dose of 6 g for 3 months (n = 20). Significant up-regulation of vascular endothelial growth factor (VEGF) was found immunochemically in sera of l-arginine-treated patients as compared to control individuals. Serum MMP-2 and -9 activities were dramatically reduced after l-arginine treatment. Decrease in circulating levels of angiostatin and degradation products of fibronectin, a predominant constituent of the endothelial basement membrane, could result from l-arginine-induced inhibition of MMP activities. Our findings indicate that l-arginine rebounds the angiogenic balance in favour of improving neovascularization that potentially contributes to cardiovascular benefits in CHF patients with CAD.Graphical abstract

Source: PharmaNutrition - July 10, 2018 Category: Nutrition Source Type: research